Bai M, Pearce S H, Kifor O, Trivedi S, Stauffer U G, Thakker R V, Brown E M, Steinmann B
Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA.
J Clin Invest. 1997 Jan 1;99(1):88-96. doi: 10.1172/JCI119137.
We characterized the in vivo, cellular and molecular pathophysiology of a case of neonatal hyperparathyroidism (NHPT) resulting from a de novo, heterozygous missense mutation in the gene for the extracellular Ca2+ (Ca2+(o))-sensing receptor (CaR). The female neonate presented with moderately severe hypercalcemia, markedly undermineralized bones, and multiple metaphyseal fractures. Subtotal parathyroidectomy was performed at 6 wk; hypercalcemia recurred rapidly but the bone disease improved gradually with reversion to an asymptomatic state resembling familial benign hypocalciuric hypercalcemia (FBHH). Dispersed parathyroid cells from the resected tissue showed a set-point (the level of Ca2+(o) half maximally inhibiting PTH secretion) substantially higher than for normal human parathyroid cells (approximately 1.8 vs. approximately 1.0 mM, respectively); a similar increase in set-point was observed in vivo. The proband's CaR gene showed a missense mutation (R185Q) at codon 185, while her normocalcemic parents were homozygous for wild type (WT) CaR sequence. Transient expression of the mutant R185Q CaR in human embryonic kidney (HEK293) cells revealed a substantially attenuated Ca2+(o)-evoked accumulation of total inositol phosphates (IP), while cotransfection of normal and mutant receptors showed an EC50 (the level of Ca2+(o) eliciting a half-maximal increase in IPs) 37% higher than for WT CaR alone (6.3+/-0.4 vs. 4.6+/-0.3 mM Ca2+(o), respectively). Thus this de novo, heterozygous CaR mutation may exert a dominant negative action on the normal CaR, producing NHPT and more severe hypercalcemia than typically seen with FBHH. Moreover, normal maternal calcium homeostasis promoted additional secondary hyperparathyroidism in the fetus, contributing to the severity of the NHPT in this case with FBHH.
我们对一例因细胞外Ca2+(Ca2+(o))感知受体(CaR)基因发生新生杂合错义突变导致的新生儿甲状旁腺功能亢进症(NHPT)的体内、细胞和分子病理生理学特征进行了研究。该女婴表现为中度严重高钙血症、明显骨矿化不足以及多处干骺端骨折。6周时进行了甲状旁腺次全切除术;高钙血症迅速复发,但骨病逐渐改善,恢复到类似家族性良性低钙血症性高钙血症(FBHH)的无症状状态。从切除组织中分离出的甲状旁腺细胞显示,其设定点(Ca2+(o)水平对甲状旁腺激素分泌产生半数最大抑制)显著高于正常人甲状旁腺细胞(分别约为1.8 mM和1.0 mM);在体内也观察到设定点有类似升高。先证者的CaR基因在第185密码子处出现错义突变(R185Q),而其血钙正常的父母为野生型(WT)CaR序列纯合子。突变型R185Q CaR在人胚肾(HEK293)细胞中的瞬时表达显示,Ca2+(o)诱发的总肌醇磷酸(IP)积累明显减弱,而正常受体和突变受体共转染显示,半数有效浓度(EC50,即引起IPs半数最大增加的Ca2+(o)水平)比单独的WT CaR高37%(分别为6.3±0.4 mM Ca2+(o)和4.6±0.3 mM Ca2+(o))。因此,这种新生的杂合CaR突变可能对正常CaR发挥显性负性作用,导致NHPT以及比典型FBHH更严重的高钙血症。此外,正常的母体钙稳态促进了胎儿额外的继发性甲状旁腺功能亢进,导致该病例中伴有FBHH的NHPT病情加重。